Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma

J Hepatol. 2022 Aug;77(2):566-567. doi: 10.1016/j.jhep.2022.02.004. Epub 2022 Feb 17.

Authors

Isabelle Ollivier-Hourmand¹, Manon Allaire², Jean Paul Cervoni³; Club Francophone pour l’Etude de l’Hypertension Portale

Collaborators

Club Francophone pour l’Etude de l’Hypertension Portale:
Delphine Weil, Violaine Ozenne, Pierre Emmanuel Rautou, Charlotte Bouzbib, Sabrina Sidali, Frédéric Oberti, Maeva Guillaume, Paul Castellani, Paul Calame, Sandrine Barge, Christophe Bureau

Affiliations

¹ Department of Hepatogastroenterology, University Hospital, Caen, France. Electronic address: [email protected].
² Department of Hepatogastroenterology, University Hospital, La Pitié Salpétrière, Paris, France.
³ Department of Hepatology, University Hospital, Besançon, France.

PMID: 35182660
DOI: 10.1016/j.jhep.2022.02.004

No abstract available

Keywords: Baveno VII; Hepatocarcinoma; Immunotherapy; Prophylaxis; Variceal Bleeding.

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Bevacizumab / adverse effects
Carcinoma, Hepatocellular* / chemically induced
Carcinoma, Hepatocellular* / drug therapy
Humans
Hypertension, Portal* / drug therapy
Hypertension, Portal* / etiology
Liver Neoplasms* / chemically induced
Liver Neoplasms* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Bevacizumab
atezolizumab